Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.69B P/E - EPS this Y -19.70% Ern Qtrly Grth -
Income -40.12M Forward P/E -65.40 EPS next Y 21.50% 50D Avg Chg 13.00%
Sales 429.95M PEG -1.80 EPS past 5Y - 200D Avg Chg 28.00%
Dividend N/A Price/Book 5.83 EPS next 5Y 20.00% 52W High Chg -5.00%
Recommedations 1.70 Quick Ratio 2.77 Shares Outstanding 48.70M 52W Low Chg 75.00%
Insider Own 3.19% ROA -3.65% Shares Float 47.04M Beta 1.44
Inst Own 106.19% ROE -8.68% Shares Shorted/Prior 3.55M/3.64M Price 56.90
Gross Margin 74.84% Profit Margin -9.33% Avg. Volume 291,016 Target Price 41.13
Oper. Margin -6.17% Earnings Date Oct 30 Volume 376,693 Change 1.16%
About AtriCure, Inc.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure, Inc. News
12/23/24 AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
11/28/24 AtriCure, Inc. (NASDAQ:ATRC) Shares Could Be 26% Below Their Intrinsic Value Estimate
11/20/24 AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/07/24 AtriCure to Participate in the Stifel 2024 Healthcare Conference
11/01/24 US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
10/31/24 AtriCure Third Quarter 2024 Earnings: Beats Expectations
10/30/24 Q3 2024 AtriCure Inc Earnings Call
10/30/24 AtriCure Inc (ATRC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
10/29/24 AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10/29/24 AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
10/29/24 AtriCure: Q3 Earnings Snapshot
10/29/24 AtriCure Reports Third Quarter 2024 Financial Results
10/28/24 AtriCure to Participate in the UBS Global Healthcare Conference
10/16/24 AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
10/15/24 AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
10/13/24 Shareholders in AtriCure (NASDAQ:ATRC) are in the red if they invested three years ago
10/11/24 AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
10/08/24 AtriCure to Announce Third Quarter 2024 Financial Results
10/01/24 AtriCure Receives CE-Mark for the EnCompass® Clamp
09/18/24 Here’s Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
ATRC Chatroom

User Image ClaraStone1043 Posted - 1 week ago

$ATRC AITX is revolutionizing AI-driven security solutions with RADCam, the world’s first talking security camera.

User Image NVDAMillionaire Posted - 2 weeks ago

$ATRC AtriCure (NASDAQ:ATRC) – Delivering Innovation and Driving Growth in the Cardiac Ablation Market https://beyondspx.com/article/atricure-nasdaq-atrc-delivering-innovation-and-driving-growth-in-the-cardiac-ablation-market

User Image Estimize Posted - 11/27/24

Wall St is expecting -0.16 EPS for $ATRC Q4 [Reporting 02/25 AMC] http://www.estimize.com/intro/atrc?chart=historical&metric_name=eps&utm_c

User Image TheLionStock Posted - 1 month ago

📈 Stock Performance for $ATRC over the Last Month: Opening Price: $28.92 Closing Price: $35.74 Highest Price: $38.34 Lowest Price: $27.64

User Image Laynester Posted - 1 month ago

$ATRC $INTC $DMRC $SLF $ALK Top 5 Percentage leaders in the portfolio at 2:30pm 11/5/2024. See you at the close!

User Image healthcareguru Posted - 10/30/24

$ATRC fade this pig…the squeeze is over. $30 PT. 👎 $IHI $XLV

User Image MaverikIT Posted - 10/30/24

@IsabellaDC @net0trader $ATRC $GRMN - nice $XPO - keep on trucking - logistic$ in demand

User Image IN0V8 Posted - 10/30/24

$ATRC Opportunity Oppenheimer raises target price to $36 from $32 Canaccord Genuity raises target price to $53 from $49 Needham raises target price to $40 from $34 Stifel raises target price to $36 from $26

User Image OpenOutcrier Posted - 10/30/24

$ATRC (+17.2% pre) AtriCure Inc (ATRC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges https://ooc.bz/l/46195

User Image briefingcom Posted - 10/30/24

Gapping up: $NRDS +28.7% $RDDT +20.1 $ATRC +15.5% $GRMN +14.5% $UIS +11.3%

User Image LuckEtradER Posted - 10/29/24

$ATRC nice!

User Image DonCorleone77 Posted - 10/29/24

$ATRC AtriCure narrows FY24 EPS view to (80c)-(74c) from (82c)-(74c), consensus (79c) Raises FY24 revenue view tot $459M-$462M from $456M-$461M, consensus $458.11M.

User Image DonCorleone77 Posted - 10/29/24

$ATRC AtriCure reports Q3 adjusted EPS (17c), consensus (19c) Reports Q3 revenue $115.9M, consensus $112.25M. "Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business," said Michael Carrel, President and Chief Executive Officer at AtriCure. "During the quarter, we launched several new products in the United States and Europe, leading to an acceleration in growth along with continued improvement in profitability and positive cash flow generation. Our results are a testament to our commitment to expand access to our innovative solutions for patients and providers worldwide."

User Image Estimize Posted - 10/28/24

$ATRC analysts on Estimize are expecting 5.00% YoY EPS growth for Q3, up from -41.67% in Q2 [Reporting Tomorrow 10/29 AMC] http://www.estim

User Image RocketThief Posted - 2 months ago

$ATRC train has left the station

User Image LuckEtradER Posted - 3 months ago

$ATRC

User Image LuckEtradER Posted - 3 months ago

$ATRC she’s been on a nice little recovery as of late. Nice move from $19/$20

User Image Stock_Titan Posted - 08/27/24

$ATRC AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device https://www.stocktitan.net/news/ATRC/atri-cure-announces-that-the-first-patient-has-been-treated-with-the-8s6rmfw3m2ad.html

User Image SharePlanner Posted - 4 months ago

I was intrigued quite a bit by $ATRC coming into the week, but what I didn't like was the risk management side of the trade of about 7%, considering how overbought the market is, and healthcare specifically. Love the triple bottom breakout though.

User Image Stock_Titan Posted - 4 months ago

$ATRC AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation https://www.stocktitan.net/news/ATRC/atri-cure-receives-expanded-ce-mark-indication-for-atri-clip-r-ppsyknhr51nu.html

User Image insiderbuyingselling Posted - 4 months ago

$ATRC new insider selling: 3500 shares. http://insiderbuyingselling.com/?t=ATRC

User Image StockInvest_us Posted - 4 months ago

Signal alert: $ATRC - Oversold Trend Short (Undervalued) https://stockinvest.us/l/ZidwLrKzZN

User Image RocketThief Posted - 4 months ago

$ATRC going to start building a long play here - trading about ~2x sales, positive cash flow, low debt, guide growing 15% Y/Y, maybe takeover target (EW rumors, but fits a lot of big co. portfolios)

User Image AnaChart Posted - 07/31/24

$ATRC https://anachart.com/wp-content/uploads/ana_temp/1722427300_soc-img.jpg

User Image NVDAMillionaire Posted - 07/30/24

$ATRC AtriCure (NASDAQ:ATRC) Poised for Continued Growth Amid Competitive Landscape http://beyondspx.com/2024/07/30/atricure-nasdaqatrc-poised-for-continued-growth-amid-competitive-landscape/

User Image Estimize Posted - 07/30/24

$ATRC beats the Estimize EPS Consensus by 1c and the Estimize Revenue Consensus by $0.73M. Reports FQ2 earnings of -17c EPS and $116.27... http://www.estimize.com/atrc/fq2-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image epsguid Posted - 07/30/24

$ATRC reported a loss of $0.17, consensus was ($0.15) via @eWhispers #epsmiss http://eps.sh/d/atrc

User Image RockyTSTH Posted - 07/30/24

$ATRC AtriCure Q2 2024 GAAP EPS $(0.17), Inline, Sales $116.30M Beat $116.18M Estimate

User Image Stock_Titan Posted - 07/30/24

$ATRC AtriCure Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ATRC/atri-cure-reports-second-quarter-2024-financial-b0gk26vz5gdt.html

User Image Estimize Posted - 07/30/24

$ATRC reports after the close, Estimize Consensus -0.01 EPS and -0.70M Revs compared to WS http://www.estimize.com/atrc/fq2-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

Analyst Ratings
BTIG Buy Jul 31, 24
JP Morgan Overweight Jul 31, 24
Stifel Buy Jul 31, 24
Needham Buy Jul 31, 24
Piper Sandler Overweight Jul 31, 24
Needham Buy Jul 8, 24
Canaccord Genuity Buy May 2, 24
JP Morgan Overweight May 2, 24
Needham Buy May 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Nov 01 Sell 34.43 1,248 42,969 30,789 11/03/23
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Jul 26 Sell 57.09 3,417 195,077 32,037 07/28/23
Prange Karen Director Director Jun 08 Sell 47.89 713 34,146 16,140 06/12/23
Dahlquist Karl S. Chief Legal Officer Chief Legal Officer Jun 06 Sell 47.03 1,422 66,877 34,897 06/07/23
Yuen Maggie Director Director May 26 Sell 47.04 4,313 202,884 4,682 05/30/23
Collar Mark A Director Director Mar 13 Option 9.30 10,000 93,000 100,871 03/15/23
WHITE ROBERT S. Director Director Aug 31 Option 8.48 15,000 127,200 55,799 09/02/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer May 13 Sell 42.69 3,203 136,736 17,621 05/17/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Apr 08 Sell 61.59 282 17,368 20,824 04/12/22
Collar Mark A Director Director Mar 16 Option 8.40 10,000 84,000 87,307 03/18/22
WHITE ROBERT S. Director Director Mar 03 Option 8.48 15,000 127,200 37,235 03/07/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Mar 04 Sell 67.66 1,409 95,333 21,106 03/07/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Mar 02 Sell 69.86 4,885 341,266 22,515 03/04/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Feb 11 Sell 67.97 2,490 169,245 20,340 02/15/22
Austin Tonya Chief Human Resource.. Chief Human Resources Officer Jan 14 Sell 66.11 2,719 179,753 22,830 01/18/22
WEHRWEIN SVEN Director Director May 05 Option 19.95 5,000 99,750 17,686 05/05/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Feb 04 Option 21.04 25,000 526,000 529,795 02/04/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Feb 04 Sell 60 25,000 1,500,000 504,795 02/04/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Jan 13 Option 21.04 25,000 526,000 529,795 01/13/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Jan 13 Sell 59 25,000 1,475,000 504,795 01/13/21
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 28 Option 21.04 25,000 526,000 529,457 12/28/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 28 Sell 58 25,000 1,450,000 504,504 12/28/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 23 Option 21.04 74,751 1,572,761 529,504 12/23/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 23 Sell 56 74,751 4,186,056 504,504 12/23/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 21 Option 13.48 125,249 1,688,357 554,753 12/21/20
CARREL MICHAEL H President, CEO, & Di.. President, CEO, & Director Dec 21 Sell 51.63 125,249 6,466,606 504,504 12/21/20